Bavarian Nordic AS BAVA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Mpox vaccine maker Bavarian Nordic's stock jumps 10% as European country places jumbo order for doses
-
'Mpox is not the new COVID,' says WHO, as it urges greater solidarity with Africa amid outbreak
-
Mpox vaccine maker's stock continues to surge
-
Bavarian Nordic Submits Data to EMA to Extend Mpox/Smallpox Vaccine Approval to Adolescents
-
Bavarian Nordic Announces FDA Acceptance and Priority Review of the BLA for its Chikungunya Vaccine
-
Bavarian Nordic Receives USD 156.8 Million from the U.S. Government for Additional Smallpox/Mpox Vaccine Production
Trading Information
- Previous Close Price
- DKK 221.10
- Day Range
- DKK 215.60–222.30
- 52-Week Range
- DKK 125.55–300.00
- Bid/Ask
- DKK 218.70 / DKK 218.90
- Market Cap
- DKK 17.21 Bil
- Volume/Avg
- 253,549 / 707,664
Key Statistics
- Price/Earnings (Normalized)
- 13.54
- Price/Sales
- 2.82
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- 0.16%
Company Profile
Bavarian Nordic AS is a biotechnology company focused on the research, development, manufacturing, and commercialization of life-saving vaccines. The vast majority of the company's revenue is generated in the United States, Germany, and other geographic markets. Its products include Encepur, Jynneos, Rabipur, Vaxchora and Vivotif.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 1,381
- Website
- https://www.bavarian-nordic.com
Comparables
Valuation
|
Metric
|
BAVA
|
300149
|
GUBRA
|
|---|---|---|---|
Price/Earnings (Normalized) | 13.54 | — | — |
Price/Book Value | 1.65 | 2.78 | 17.02 |
Price/Sales | 2.82 | 3.53 | 35.87 |
Price/Cash Flow | 8.40 | 28.75 | — |
Price/Earnings
BAVA
300149
GUBRA
Financial Strength
|
Metric
|
BAVA
|
300149
|
GUBRA
|
|---|---|---|---|
Quick Ratio | 0.91 | 1.46 | 7.16 |
Current Ratio | 1.48 | 1.71 | 7.24 |
Interest Coverage | 5.69 | −32.05 | −11.85 |
Quick Ratio
BAVA
300149
GUBRA
Profitability
|
Metric
|
BAVA
|
300149
|
GUBRA
|
|---|---|---|---|
Return on Assets (Normalized) | 9.32% | −34.73% | −7.51% |
Return on Equity (Normalized) | 13.26% | −54.47% | −9.63% |
Return on Invested Capital (Normalized) | 13.68% | −38.80% | −9.11% |
Return on Assets
BAVA
300149
GUBRA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Srytkgtg | Ftzs | $526.2 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Vfwgfdgx | Jxqmkj | $115.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Xlpbkptlk | Qznzdc | $109.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Cbrvhjjs | Rzryzv | $34.2 Bil | |||
| argenx SE ADR
ARGX
| Ymxfcvfkb | Dzn | $31.5 Bil | |||
| BioNTech SE ADR
BNTX
| Fjdphhdkv | Yds | $28.9 Bil | |||
| Moderna Inc
MRNA
| Sffjkfhh | Kld | $22.6 Bil | |||
| United Therapeutics Corp
UTHR
| Cqxdbgcd | Mxp | $15.6 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Dmcvpyxpw | Rjprrb | $13.1 Bil | |||
| Incyte Corp
INCY
| Nsnqwdxzv | Dbtzw | $12.7 Bil |
United States